Efficacy and dose of afatinib in patients with non ‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment

ConclusionsThe efficacy of afatinib was similar to that identified in the global data without unexpected adverse events. Survival analyses support the currently approved dose of afatinib as first ‐line treatment for NSCLC.

Source: Thoracic Cancer - April 3, 2021 Category: Cancer & Oncology Authors: Hayoung Choi, Jae ‐Kyeong Lee, Hyung‐Joo Oh, Min‐Seok Kim, Bo Gun Kho, Cheol Kyu Park, In‐Jae Oh, Young‐Chul Kim Tags: ORIGINAL ARTICLE Source Type: research